Optimising management of chronic heart failure
- 17 November 2009
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 374 (9704), 1808-1809
- https://doi.org/10.1016/s0140-6736(09)61992-9
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trialThe Lancet, 2009
- Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trialThe Lancet, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE IIThe Lancet, 2000
- Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failureJournal of the American College of Cardiology, 1999
- Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart FailureCirculation, 1999
- Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failureAmerican Heart Journal, 1999
- Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparisonEuropean Heart Journal, 1998
- Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failureEuropean Heart Journal, 1996